Vaccines and compositions against
View Patent ↗Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae . The antigens may be used therapeutically or prophylactically.
1. A vaccine formulation comprising a pharmaceutically acceptable carrier, an effective amount of an adjuvant, a first polypeptide consisting essentially of the amino acid sequence of SEQ ID NO: 9, and a second polypeptide consisting essentially of the amino acid sequence of SEQ ID NO: 10, characterized in that, when administered to a subject, the vaccine formulation elicits an immune response to S. pneumonia in the subject.
2. The vaccine formulation of claim 1 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:9, and the second polypeptide consists of the amino acid sequence of SEQ ID NO: 10.
3. The vaccine formulation of claim 1 , which contains substantially no other S. pneumoniae polypeptide other than polypeptides having an amino acid sequence comprising any of SEQ ID NOS: 1-13.
4. The vaccine formulation of claim 1 , wherein the vaccine formulation comprises at least one polypeptide conjugated to an immunogenic carrier.
5. The vaccine formulation of claim 1 , which comprises at least one lipidated polypeptide.
6. The vaccine formulation of claim 1 , further comprising an excipient.
7. The vaccine formulation of claim 1 , wherein the adjuvant is an agonist of toll-like receptors (TLRs).
8. The vaccine formulation of claim 1 , wherein the adjuvant is alum.
9. The vaccine formulation of claim 1 , wherein the vaccine formulation comprises 1-1000 μg of each polypeptide and 1-250 μg of the adjuvant.
10. The vaccine formulation of claim 1 , characterized in that the vaccine formulation induces a T H 17 cell response that is at least 1.5-fold greater than a T H 17 response induced by a control.
11. The vaccine formulation of claim 1 , characterized in that, when administered to a non-colonized or uninfected subject, the vaccine formulation inhibits infection by S. pneumonia in the subject.
12. The vaccine formulation of claim 1 , characterized in that, when administered to a subject, the vaccine formulation inhibits S. pneumonia colonization in the subject.
13. The vaccine formulation of claim 1 , characterized in that, when administered to a subject, the vaccine formulation inhibits one or more S. pneumonia symptoms in the subject.